Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label
Dusquetide Oral Lesions
.
Show all posts
Showing posts with label
Dusquetide Oral Lesions
.
Show all posts
Tuesday, August 13, 2024
FDA Grants Soligenix Fast Track Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
›
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing ...
›
Home
View web version
